Company intelligence / Profile preview

Soin Bioscience

Dayton, Ohio, United States

Ownership: Private
Development stage: Other

Overview

Soin Bioscience is a clinical-stage biotechnology company focused on developing novel pharmacological treatments for chronic pain and neurological disorders. The company's lead program, TV-1001, is a sodium channel blocker being evaluated for the treatment of complex regional pain syndrome (CRPS) and other neuropathic pain conditions. By targeting specific sodium channel isoforms, Soin Bioscience aims to provide effective pain relief with a reduced side-effect profile compared to traditional analgesics. The company is led by experienced clinicians and researchers dedicated to addressing significant unmet needs in pain management.

Therapeutic areas: CardiovascularNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Soin Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Soin Bioscience.

Explore the full profile